425.11 Hypertrophic cardiomyopathy
A cardiovascular disease that is characterized by an abnormally thick heart muscle.
ICD-9 code 425.1 for Hypertrophic cardiomyopathy is a medical classification as listed by WHO under the range -OTHER FORMS OF HEART DISEASE (420-429). Subscribe to Codify and get the code details in a flash.
ICD-9-CM codes are used in medical billing and coding to describe diseases, injuries, symptoms and conditions. ICD-9-CM 425.1 is one of thousands of ICD-9-CM codes used in healthcare. Although ICD-9-CM and CPT codes are largely numeric, they differ in that CPT codes describe medical procedures and services.
ICD-10-CM allows the different types of cardiomyopathy to have a unique code. The following are the codes included under category I42: • I42.1, Obstructive hypertrophic cardiomyopathy (includes hypertrophic subaortic stenosis);
• Dilated cardiomyopathy (ICD-9-CM code 425.4) is the most common type in which the left ventricle becomes enlarged and can no longer pump blood throughout the body. This type generally occurs in middle-aged people. When the cardiomyopathy is associated with alcoholism, assign code 425.5 for alcoholic cardiomyopathy.
Types of Hypertrophic Cardiomyopathy Obstructive: The most common type, hypertrophic obstructive cardiomyopathy (HOCM) means the wall (septum) between the left ventricle and right ventricle thickens. This can block (obstruct) blood flow from the left ventricle to the aorta (the body's main artery).
Hypertrophic obstructive cardiomyopathy (HOCM), historically referred to as idiopathic hypertrophic subaortic stenosis, is a relatively common disorder. HOCM is a significant cause of sudden cardiac death in young people, including well-trained athletes, and affects men and women equally across all races.
HOCM can lead to clinical heart failure, life-threatening arrhythmias, mitral regurgitation and sudden cardiac death.
Hypertrophic cardiomyopathy is usually caused by changes in genes (gene mutations) that cause the heart muscle to thicken. Hypertrophic cardiomyopathy typically affects the muscular wall (septum) between the two bottom chambers of the heart (ventricles). The thickened wall might block blood flow out of the heart.
An echocardiogram is commonly used to diagnose hypertrophic cardiomyopathy. This test uses sound waves (ultrasound) to see if the heart's muscle is unusually thick. It also shows how well the heart's chambers and valves are pumping blood. Electrocardiogram (ECG or EKG).
Hypertrophic cardiomyopathy (HCM) is diagnosed on the basis of left ventricular (LV) hypertrophy for which there is insufficient explanation (e.g. mild hypertension or mild aortic stenosis with marked hypertrophy). Echocardiography is an invaluable tool in the diagnosis and follow-up of patients with HCM.
It can cause abnormal heart rhythms (arrhythmias) that may be life threatening. People with familial hypertrophic cardiomyopathy have an increased risk of sudden death, even if they have no other symptoms of the condition.
Hypertrophic cardiomyopathy is most often caused by abnormal genes in the heart muscle. These genes cause the walls of the heart chamber (left ventricle) to become thicker than normal.
The classic ECG finding in hypertrophic obstructive cardiomyopathy is large dagger-like “septal Q waves” in the lateral — and sometimes inferior — leads due to the abnormally hypertrophied interventricular septum. Criteria for left ventricular hypertrophy is usually present.
The most common presenting symptom of hypertrophic cardiomyopathy is dyspnea. Patients also can develop syncope, palpitations, angina, orthopnea, paroxysmal nocturnal dyspnea, dizziness, congestive heart failure, and sudden cardiac death. The latter represents the most devastating presenting symptom.
Mean age at HCM death was 56 years (range, 7-87 years); 21 deaths (72%) were considered premature, occurring before age 75 years (Figure 1). The other 8 patients (28%) died of HCM at age 76 to 87 years and, therefore, achieved statistical life expectancy (Figure 1).
There is no cure for hypertrophic cardiomyopathy (HCM). However, several treatments are available to relieve or eliminate symptoms and provide protection against sudden death, providing the vast majority of HCM patients the opportunity to achieve normal longevity with an excellent quality of life.
Agents to reduce pre- or afterload (such as nitrate, ACE inhibitors, nifedipine-type calcium antagonists) are contraindicated with HOCM due to possible aggravation of the outflow tract obstruction.